A Phase 3 interventional study of ICA-17043 in Sickle Cell Disease, sponsored by Icagen. Terminated at 49 sites in 6 countries. Open to participants aged 16 Years to 65 Years. Per ClinicalTrials.gov, last updated 2008-03-27.
Sponsored by Icagen · Phase 3, Interventional, and Treatment
The purpose of this study is to compare the effects of ICA-17043 to placebo with or without hydroxyurea (an oral drug used for treatment of sickle cell disease) in patients with sickle cell disease who have had 2 or more acute sickle-related painful crises requiring a visit to a medical facility within the past 12 months.
1,103 studies on the registry are indexed under Anemia, Sickle Cell; 235 are open to participants now.
This study's enrollment of 297 is above the median of 40 across 750 interventional studies indexed under Anemia, Sickle Cell.
Browse Anemia, Sickle Cell studies →Icagen is the lead sponsor of 5 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Sickle Cell Crisis Rate
Time frame: 52 weeks
Time to First, Second, and Third Crisis
Time frame: 52 Weeks
Maximum Crisis Morbidity Ranking
Time frame: 52 Weeks
Efficacy Related Laboratory Parameters
Time frame: 52 Weeks
Quality of Life
Time frame: 52 Weeks
Health Economics
Time frame: 52 Weeks
This study is terminated, as verified in Sep 2007. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Icagen